8-K/A: Accendra Health Completes P&HS Sale, Repays Debt

Accendra Health, Inc. completed the sale of its Products & Healthcare Services business for $375 million and amended its receivables program, using proceeds to repay $280 million in long-term debt.

Summary

• Accendra Health, Inc. (formerly Owens & Minor, Inc.) completed the sale of its Products & Healthcare Services (P&HS) business on December 31, 2025.
• The P&HS business was sold for an aggregate of $375 million in cash, subject to certain adjustments.
• The company also contributed Rollover Company Securities in exchange for non-voting, passive Rollover Units in Dominion Healthcare Holdings, L.P. (Purchaser Parent).
• These Rollover Units entitle Accendra Health to 50% of distributions made by Purchaser Parent after aggregate distributions of $310 million, until the company receives $200 million, and 5% of distributions exceeding these priority returns.
• The Receivables Sale Program was amended on December 31, 2025, allowing for the sale of accounts receivable with an aggregate outstanding amount not to exceed $150 million.
• On the Closing Date, $94 million of eligible accounts receivable were sold under the amended program.
• Proceeds from the transactions, including $66 million from the receivables sale, were used to remove a $160 million intercompany payable related to the P&HS accounts receivable.
• Accendra Health anticipates using the proceeds from the P&HS sale to repay the $280 million current portion of its long-term debt.
• Unaudited pro forma condensed consolidated financial statements reflect the P&HS segment as discontinued operations, with pro forma net revenue for 2024, 2023, and 2022 at $2.68 billion, $2.55 billion, and $2.06 billion, respectively.

Sentiment

Score: 6

Explanation: The completion of a significant divestiture and subsequent debt repayment are positive for financial restructuring and focus. However, the pro forma financials show a substantial reduction in revenue and a shift to net losses in some periods, indicating the divested segment's contribution. The retained equity interest offers future upside, but the immediate impact is a smaller, less revenue-generating entity.

Positives

• Successful completion of the P&HS business sale for $375 million in cash, providing significant liquidity.
• Anticipated repayment of $280 million in current long-term debt, which will reduce financial leverage and improve the balance sheet.
• The amendment of the Receivables Sale Program provides ongoing liquidity by allowing the sale of up to $150 million in accounts receivable, with $94 million already sold.
• Accendra Health retains a 5% equity interest as Rollover Units in the Purchaser Parent, offering potential for future distributions and long-term value.

Negatives

• Pro forma net revenue is significantly reduced across all presented years due to the divestiture of the P&HS segment (e.g., from $10.7 billion to $2.68 billion in 2024), indicating a much smaller operational footprint.
• Pro forma net loss for 2024 increased to $(366,510) thousand from $(362,686) thousand as reported, and for 2022, it shifted from a net income of $22,389 thousand to a net loss of $(53,770) thousand, suggesting the divested segment was a significant contributor to revenue and, in some periods, profitability.
• The company's total assets and liabilities are substantially reduced post-transaction, reflecting a significant contraction in scale.

Risks

• The company refers to existing risks detailed under 'Risk Factors' in its Annual Report on Form 10-K for the year ended December 31, 2024, and any updates to those risks or new risks contained in subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC.

Future Outlook

The company anticipates using the proceeds from the P&HS business sale and the Receivables Sale Program to repay $280 million of its current long-term debt. The amended Receivables Sale Program is scheduled to terminate on October 18, 2027, providing ongoing liquidity for managing accounts receivable.

Management Comments

• The report was signed by Heath H. Galloway, Executive Vice President, General Counsel and Corporate Secretary, confirming the due authorization of the filing.

Industry Context

The divestiture of the P&HS business suggests a strategic realignment for Accendra Health, potentially focusing on its remaining core operations. Such divestitures are common in the healthcare industry as companies streamline portfolios to enhance efficiency or focus on higher-growth segments. The amended receivables program provides a mechanism for managing working capital and liquidity in a dynamic market, which is a standard financial practice.

Stakeholder Impact

• Shareholders: The company's financial profile will be significantly altered, with reduced revenue and a smaller asset base, but also reduced debt. The retained equity interest offers potential future returns, subject to the Purchaser Parent's performance.
• Creditors: The anticipated repayment of $280 million in current long-term debt will improve the company's debt profile and reduce immediate obligations, potentially enhancing creditworthiness.
• Employees: The divestiture of the P&HS business likely impacts employees associated with that segment, though the filing does not provide specific details on personnel changes or workforce reductions.

Next Steps

• Final determination of the purchase price for the P&HS business, subject to adjustments for cash, indebtedness, net working capital, and transaction expenses.
• Repayment of the $280 million current portion of long-term debt using transaction proceeds.
• Ongoing management of the Amended & Restated Receivables Sale Program until its scheduled termination on October 18, 2027.

Key Dates

Recommendation

The completion of the P&HS business sale and the subsequent debt repayment are positive steps towards streamlining operations and improving the balance sheet. However, the pro forma financials indicate a significantly smaller revenue base and a shift to net losses in some periods, suggesting a period of adjustment and re-evaluation of the company's core profitability post-divestiture. The retained equity interest offers some long-term upside, but the immediate impact warrants a 'hold' as investors assess the performance of the newly structured entity.

Keywords

Accendra Health, Owens & Minor, P&HS business sale, divestiture, receivables sale program, debt repayment, pro forma financials, healthcare services, SEC filing, 8-K/A